DebioPharm has launched its gonadotropin releasing hormone (GnRH) agonist analogue Salvacyl (extended-release triptorelin), for the treatment of sexual deviancy by the reversible reduction of serum testosterone to castrate levels, in Germany and Belgium.
DebioPharm's Salvacyl launched in EU for sexual deviancy
DebioPharm has launched its gonadotropin releasing hormone (GnRH) agonist analogue Salvacyl (extended-release triptorelin), for the treatment of sexual deviancy by the reversible reduction of serum testosterone to castrate levels, in Germany and Belgium.
More from Immunological
• By
The biotech is banking on itolizumab’s longer-term efficacy as well as unmet need in frontline acute graft-versus-host disease as it prepares to meet with the FDA.
• By
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.
• By
Obefazimod has been heralded as a potential blockbuster for ulcerative colitis and there will be great interest in the readout of Phase III induction trials in the third quarter of this year.
• By
The development could highlight the power of competitive market forces over government price controls or suggest Medicare price negotiation is enhancing competitive market forces.
More from Therapeutic Category
• By
After a long wait for patients, Vykat has become the first drug approved for Prader-Willi syndrome symptoms, opening the market up for Soleno and future challengers.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.
• By
J&J is confident that its bispecific antibody/kinase inhibitor combo’s overall survival win over AstraZeneca’s single-agent pill will shift the standard of care.